The clinical professor of medicine, Helen Diller Family Comprehensive Cancer Center, UCSF, discussed data from both the CARTITUDE-1 and CARTITUDE-2 studies.
Ciltacabtagene autoleucel (cilta-cel) produced deep and durable responses in heavily-pretreated patients with multiple myeloma, according to data from the phase 1/2 CARTITUDE-1 study (NCT03548207).1,2
These data were presented at the 63rd Annual American Society of Hematology (ASH) Meeting, December 11-14, 2021, by Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, and associate director, Myeloma Program, University of California San Francisco, and co-leader, Cancer Immunology & Immunotherapy Program, Helen Diller Family Comprehensive Cancer Center.
Also presented at ASH 2021 were results from the CARTITUDE-2 study (NCT04133636) which is evaluating cilta-cel as an earlier line of therapy in patients with only 1 to 3 prior lines of therapy.3 Progression-free survival (PFS) at 6 months was 90% (95% CI, 65.6–97.4).
GeneTherapyLive spoke with Martin to learn more about the CARTITUDE-1 and CARTITUDE-2 studies. He discussed positive safety and efficacy data seen in both studies and cilta-cel's place in the multiple myeloma treatment landscape.
Keys to a Successful Cell and Gene Therapy Launch
February 16th 2025The success of cell and gene therapies relies not just on approvability but on affordability and accessibility. Innovative manufacturing, automation, and digital tools are key to expanding patient access and ensuring commercial viability.